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Abstract
Narrow arterioles in the retina have been shown to predict hypertension as well as other vascular diseases, likely through an
increase in the peripheral resistance of the microcirculatory flow. In this study, we performed a genome-wide association
study in 18,722 unrelated individuals of European ancestry from the Cohorts for Heart and Aging Research in Genomic
Epidemiology consortium and the Blue Mountain Eye Study, to identify genetic determinants associated with variations in
retinal arteriolar caliber. Retinal vascular calibers were measured on digitized retinal photographs using a standardized
protocol. One variant (rs2194025 on chromosome 5q14 near the myocyte enhancer factor 2C MEF2C gene) was associated
with retinal arteriolar caliber in the meta-analysis of the discovery cohorts at genome-wide significance of P-value,561028.
This variant was replicated in an additional 3,939 individuals of European ancestry from the Australian Twins Study and
Multi-Ethnic Study of Atherosclerosis (rs2194025, P-value = 2.11610212 in combined meta-analysis of discovery and
replication cohorts). In independent studies of modest sample sizes, no significant association was found between this
variant and clinical outcomes including coronary artery disease, stroke, myocardial infarction or hypertension. In conclusion,
we found one novel loci which underlie genetic variation in microvasculature which may be relevant to vascular disease.
The relevance of these findings to clinical outcomes remains to be determined.
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Introduction
The retinal microcirculation provides a unique window for non-
invasive visualization of the human microcirculation in vivo.
Retinal vascular caliber has been shown to predict cardiovascular
diseases [1,2,3,4]. Narrow retinal arterioles have been documented
to be a risk factor for subsequent development of hypertension
[5,6,7,8], diabetes mellitus [9,10,11], stroke [12], coronary heart
disease [3,4,13] and cerebral small vessel disease [14,15,16]. The
most consistent evidence is that narrow retinal arteriolar caliber,
reflecting widespread peripheral vasoconstriction and arteriolo-
sclerosis, precedes clinically manifest hypertension and, therefore,
is a pre-clinical marker for subsequent elevation of blood pressure
[17,18].
Recent studies suggest that genetic factors may influence retinal
vascular caliber [19,20,21,22]. The identification of genetic
determinants of retinal vascular caliber may provide further
insights into the relationship between retinal vessels and cardio-
vascular diseases. We recently reported on four novel loci
associated with retinal venular caliber in 15,358 subjects from
the Cohorts for Heart and Aging research in Genomic Epidemi-
ology (CHARGE) consortium. However, there was no genome-
wide significant association between any single nucleotide poly-
morphism (SNP) and retinal arteriolar caliber [23].
In this study, we extended our discovery phase by including the
Blue Mountains Eye Study (BMES) [24], which measured retinal
vascular caliber and recently completed genome-wide marker
genotyping of 2,430 participants. We replicated our findings in the
European white populations of the Multi-Ethnic Study of
Atherosclerosis (MESA) [25] and the Australian Twins Study
[26]. Finally, we sought to determine whether any of the loci are
also associated with major macrovascular disease outcomes in
independent cohorts of European ancestry, including hypertension
in the Global Blood Pressure Genetics (Global BPgen) [27],
Genetic Loci for Retinal Arteriolar Caliber
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e65804
coronary artery disease (CAD) in the Wellcome Trust Case
Control Consortium (WTCCC) [28], myocardial infarction and
stroke in the Heart and Vascular Study (HVH) [29,30] and
incident/prevalent coronary artery disease and incident ischemic
stroke in the Genetics of Diabetes Audit and Research in Tayside
Scotland (GoDARTS) [31].
Results
Study Cohorts
The discovery phase examined data from 18,722 individuals of
European ancestry from the CHARGE consortium [32] and
BMES [24]. The sample size for the replication phase was 3,939
individuals, also of European ancestry. Characteristics of the
cohorts in both the discovery and replication phases are presented
in Table 1.
Meta-analysis of Discovery Cohorts
A total of 2,137,729 genotyped or imputed SNPs post quality
control were common to all five cohorts. The QQ-plot
(Figure 1A) showed departure from the line of identity around
P-values ,1.061023, with an overall genomic inflation factor of
1.03. The Manhattan plot of minus log-transformed P-values for
each SNP against its physical position showed two loci reaching
genome-wide significance, one on chromosome 5 and the other on
chromosome 17 (Figure 1B). These included a cluster of 31 SNPs
in high linkage disequilibrium on chromosome 5 between the
genes TMEM161B (transmembrane protein 161B) and MEF2C
(myocyte enhancer factor 2C) and 2 SNPs on chromosome 17,
with a number of genes spanning the region including SFRS2
(serine/arginine-rich splicing factor 2), MFSD11 (major facilitator
superfamily domain containing 11), JMJD6 (jumonji domain
containing 6) and MXRA7 (matrix-remodelling associated 7)
(Figure 2). A third locus on chromosome 13 exhibited suggestive
evidence of an association with retinal arteriolar caliber at P-value
,1026, on FLT1 (fms-related tyrosine kinase 1, also known as the
vascular endothelial growth factor) (Table 2). The coded allele for
each SNP was presented as the allele that decreased arteriolar
caliber; and we referred to this as the effective allele. A second
model was fitted for the top index SNPs in each discovery cohort,
with additional adjustment for hypertension and diabetes status.
The association of the three index SNPs with retinal arteriolar
caliber remained unchanged (Table S1). Collectively, these
variants only explained 0.52 to 1.25% of the overall variance in
retinal arteriolar caliber in each of the discovery cohorts. As these
index SNPs were imputed SNPs, we also presented the next best
index SNPs directly observed in Table S2.
Replication in Independent Cohorts
Table 3 shows results from each of the two replication cohorts,
MESA and Australian Twins Study, for the three index SNPs on
chromosomes 5, 13 and 17 that were taken forward for replication
from the discovery phase. Minor allele frequencies in the
replication cohorts were very similar to those in the discovery
cohorts. Of the three variants that were taken forward for
replication, two SNPs replicated in the combined analyses of the
replication cohorts. These included rs2194025 on chromosome 5
(P-value= 3.7461023) and rs3744061 on chromosome 17 (P-
value = 1.5161023). In both instances, the directions of effect in
the replication cohorts were consistent with the directions of effect
observed in the discovery phase (Table 3). Index SNP rs2194025
on chromosome 5 yielded an overall P-value of 2.11610212 in the
meta-analysis including both discovery and replication cohorts.
Each additional copy of the effective allele was associated with a
decrease of 1.6 mm in the mean retinal arteriolar caliber. Similar
Table 1. Baseline characteristics of the discovery and replication cohorts.
Discovery cohorts Replication cohorts
AGES ARIC CHS RS BMES Australian Twins MESA
N 2,949 7,260 1,263 4,820 2,430 1,769 2,170
Age (years) 76.2 (5.4) 59.9 (5.6) 78.4 (4.2) 68.0 (8.2) 66.8 (9.0) 22.0 (11.9) 62.2 (10.0)
[66–94] [50–71] [72–95] [55–99] [49–96] [5–90] [44–84]
Proportion female (%) 57.5 53.5 63.0 59.0 56.9 56.0 49.0
CRAE (mm) 139.7 (13.4) 135.1 (12.8) 138.8 (14.2) 150.0 (14.4) 160.0 (15.4) 164.3 (13.6) 142.7 (14.3)
[74.0–221.4] [72.6–187.2] [77.6–191.0] [98.5–235.4] [91.4, 210.7] [83.6–205.2] [83.3–219.2]
CRVE (mm) 202.0 (19.5) 199.5 (19.1) 196.5 (19.2) 226.0 (20.1) 224.6 (20.2) 248.0 (19.0) 206.5 (21.1)
[123.8–273.0] [129.3–304.1] [142.5–271.7] [162.5–324.3] [150.0–311.7] [130.5–325.7] [123.6–289.9]
Body mass index (kg/m2) 27.1 (4.4) 28.0 (5.2) 26.8 (4.3) 26.3 (3.7) 27.6 (4.7) NA 27.7 (5.0)
[14.8–48.5] [14.2–59.1] [15.6–46.7] [14.2–50.7] [16.5–49.2] [16.9–49.0]
Systolic blood pressure (mmHg) 142.5 (20.2) 122.4 (18.0) 134.3 (20.4) 138.5 (22.1) 146.0 (21.4) NA 122.6 (19.9)
[92.0–253.0] [63.0–226.0] [82.0–241.0] [74.0–250.0] [90.0–235.0] [75.0–208.5]
Diastolic blood pressure (mmHg) 74.1 (20.2) 70.74 (10.0) 67.9 (10.8) 73.7 (11.4) 84.8 (10.2) NA 70.1 (9.9)
[92.0–253.0] [32.0–114.0] [15.0–110.0] [24.0–139.0] [50.0–120.0] [41.0–108.0]
Hypertension (%) 80.6 39.3 48.8 42.3 50.9 3.2 37.5
Diabetes mellitus (%) 11.4 11.9 12.3 10.0 10.3 1.0 5.4
Current smoker (%) 12.5 17.3 6.1 23.6 9.8 11.0 11.2
AGES: Age Gene/Environment Susceptibility – Reykjavik Study, ARIC: Atherosclerosis Risk in Communities Study, CHS: Cardiovascular Health Study, RS: Rotterdam Study,
BMES: Blue Mountains Eye Study. MESA: Multi-Ethnic Study of Atherosclerosis. Mean (standard deviation) [range] are given for continuous variables. Percentages are
given for categorical variables.
doi:10.1371/journal.pone.0065804.t001
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evidence of association was seen for rs2194026, a directly
genotyped SNP on chromosome 5. For SNP rs3744061 on
chromosome 17 locus, each additional copy of the effective allele
was associated with a decrease of 0.86 mm in mean arteriolar
caliber (P-value = 1.74610210); however, the next best directly
genotyped SNP rs9916811 did not replicate (P-value for discovery
cohorts = 1.0561028; P-value for discovery and replication
cohorts combined by meta-analysis = 1.7761025). SNP
rs2281827 on chromosome 13 also did not replicate consistently;
and the overall P-value in the meta-analysis including both the
discovery and replication cohorts did not reach genome-wide
significance. The regional association plots are shown in Figure 2
for all three loci.
Conditional Analyses
The coefficient of correlation between arteriolar and venular
caliber is approximately 0.6 [33,34]. To account for this
relationship, additional regression models were fitted for retinal
arteriolar caliber conditioning on retinal venular caliber. These
conditional analyses effectively removed any association with the
SNPs on chromosomes 5 and 17, although it is possible that there
is potential over-adjustment by including retinal venular caliber as
a covariate (Figure 3). Using data from the Atherosclerosis Risk
in Communities Study (ARIC) from the discovery phase, we
performed additional conditional analyses by including the index
SNPs as covariates. Conditional analysis adjusting for the
arteriolar caliber index SNP rs2194025 removed the association
at this locus on chromosome 5. The conditional analysis
attenuated the signals of the SNPs close to the index SNP, but
appeared to strengthen the associations 200 kb upstream near
TMEM161B (Figure 4). This suggests the possibility of more than
one functional variant affecting retinal arteriolar caliber on
chromosome 5. Similar results were observed when adjusting for
the venular index SNP rs17421627 [23]. The association signals
were attenuated around the retinal arteriolar index SNP.
However, association signals nearer TMEM161B and MEF2C
were largely unaffected and instead, appeared to be strengthened
(Figure 4).
Associations with Clinical End-points
We also performed in-silico look-ups of the three index SNPs,
rs2194025, rs3704461 and rs2281827, in three independent
cohorts that had information on clinical macrovascular endpoints.
They were hypertension (Global Blood Pressure Genetics – Global
BPgen) [27], coronary artery disease (Wellcome Trust Case
Control Consortium – WTCCC) [28], stroke or myocardial
infarction (Heart and Vascular Health Study – HVH) [29,30], and
incident coronary artery and ischemic stroke events in a diabetic
cohort (Go-DARTS) [31] (Table 4). A signification association
was reported for rs2281827, with prevalent ischemic heart disease
and incident ischemic stroke in the GoDARTS cohort. The allele
that decreased arteriolar caliber was associated with increased risk
of ischemic heart disease, however, the same allele was also
associated with reduced risk of incident ischemic stroke (hazard
ratio HR=0.56, P-value = 1.1461024).
Discussion
We identified one new locus on chromosome 5 which harbor
variants convincingly associated with retinal arteriolar caliber in
the meta-analysis of five cohorts of European ancestry. These
findings were replicated in two additional independent cohorts
also of European ancestry.
The locus associated with retinal arteriolar caliber on chromo-
some 5 spanned about 80 kb between TMEM161B and MEF2C.
The nearest gene,MEF2C, is a regulator of cardiac morphogenesis
and essential in the development of the right ventricle in mice
[35,36,37]. Recently, MEF2C has also been implicated in the
pathogenesis of insulin resistance, an important risk factor for
vascular disease. Myostatin is thought to be a negative regulator of
skeletal muscle growth. Deletion of the myostatin gene reduces
insulin resistance [38] and alters skeletal muscle fiber composition.
Figure 1. A) QQ-plot of –log10(observed P-values) against –log10(expected P-values) and B) Manhattan plot of –log10 transformed P-
values of retinal arteriolar caliber against their physical position.
doi:10.1371/journal.pone.0065804.g001
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The latter is thought to be mediated by altered expression of
MEF2C [39]. Given its known effect in regulating growth and
differentiation of muscle, and recent data showing that variants at
the same locus of MEF2C were also associated with bone mineral
density, it is possible that these variants act through an effect on
connective tissues that affect blood vessel morphology in general
[40]. Interestingly, the locus we found on chromosome 5 near
MEFC2 in the present analysis was also found to be associated with
retinal venular caliber [23]. Xing et al reported seven linkage
regions each for retinal arteriolar and venular caliber, and
although none of them overlapped with the findings in the current
genome-wide association analysis, three of the linkage regions
were common to both retinal arteriolar and venular calibers [19].
The associations of MEF2C locus with both retinal arteriolar and
venular calibers suggest that this locus influences retinal vessel
structure. Conditional analyses suggest the possibility of more than
one functional mechanism at this locus, either affecting one or
both of the retinal calibers.
The two loci on chromosome 13 and 17 showed less conclusive
evidences of association with retinal arteriolar caliber (Table 2,
Table 3 and Table S2). For index SNP rs2281827 on
chromosome 13, the P-value in discovery was 3.5561027 and it
failed to replicate in the replication cohorts. Although the index
SNP rs3744061 associated with retinal arteriolar caliber did show
replication, this was an imputed SNP and when we looked at the
next best genotyped SNP rs9916811, the combined P-value from
discovery and replication cohorts was 1.7761025. The index SNP
rs3744061 on chromosome 17 was located near a cluster of genes,
Figure 2. Regional association plots at the two loci that exhibit genome-wide significance at discovery stage and one locus that
showed suggestive evidence of association at P-value ,1026. A) Chromosome 5 near TMEM161B and MEF2C, B) Chromosome 17 on SFRS2
and C) Chromosome 13 on FLT. In each regional plot, the index SNP is represented by a purple circle for the meta-analysis of the five discovery studies
and a purple diamond for meta-analysis of discovery and replication studies. The remaining SNPs are colour coded according to pairwise linkage
disequilibrium (LD) with the index SNP on a scale of r2 from 0 (blue) to 1 (red). Estimated recombination rates reflect the local LD structure in the
500 kb buffer around the index SNP and plotted based on values on Hapmap II CEU. Data for gene annotations are obtained from the RefSeq track of
the UCSC Gene Browser (See LocusZoom http://csg.sph.umich.edu/locuszoom/for more details).
doi:10.1371/journal.pone.0065804.g002
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Table 3. Results for retinal arteriolar caliber for discovery cohort meta-analysis and replication cohorts.
SNP (chr: position)
Ref/Effective
allele (+) Cohort
Eff allele
freq Beta (SE) P-value Genes of interest
rs2194025 (5: 87833992) C/G Discovery cohorts combined 0.91 21.60 (0.25) 1.53610210 TMEM16B
MESA Whites 0.91 22.03 (0.76) 7.0061023 MEF2C
Australian Twins 0.91 21.14 (0.83) 1.6861021
Replication cohorts combined 0.91 21.62 (0.56) 3.7461023
Discovery+Replication cohorts
combined
0.91 21.60 (0.23) 2.11610212
Cohort Eff allele freq Beta (SE) P-value Genes of interest
rs3744061 (17: 72244998) A/G Discovery cohorts combined 0.44 20.82 (0.15) 2.4961028 SFRS2
MESA Whites 0.44 20.44 (0.45) 3.2061021 MFSD11
Australian Twins 0.45 21.75 (0.49) 3.0161024 JMJD6
Replication cohorts combined 0.45 21.04 (0.33) 1.5161023 MXRA7
Discovery+Replication cohorts
combined
0.44 20.86 (0.13) 1.74610210
Cohort Eff allele freq Beta (SE) P-value Genes of interest
rs2281827 (13: 27899721) T/C Discovery cohorts combined 0.77 20.90 (0.18) 3.5561027 FLT1
MESA Whites 0.75 20.15 (0.51) 7.7061021
Australian Twins 0.76 0.74 (0.57) 1.9261021
Replication cohorts combined 0.75 0.25 (0.38) 5.1261021
Discovery+Replication cohorts
combined
0.76 20.70 (0.16) 1.4461025
SE: standard error, OR: odds ratio, MESA: Multi-Ethnic Study of Atherosclerosis.
The allele that decreases retinal arteriolar caliber is presented as the effective allele (refer to Table 2).
doi:10.1371/journal.pone.0065804.t003
Figure 3. Regional association plots for retinal arteriolar caliber conditioned on retinal venular caliber for A) Chromosome 5 near
TMEM161B and MEF2C and B) Chromosome 17 on SFRS2. All regional plots are centered on the index SNPs, with a 500 kb buffer on both sides
of the index SNP.
doi:10.1371/journal.pone.0065804.g003
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SFRS2, MFSD11, JMJD6 and MXRA7 while the index SNP
rs2281827 on chromosome 13 was found on the vascular
endothelial growth factor receptor 1 (FLT-1/VEGFR-1). JMJD6
is a RNA splicing regulator and recently, reduction of JMJD6
expression has been found to alter splicing of the vascular
endothelial growth factor receptor 1 (FLT-1/VEGFR-1), increasing
levels of soluble FLT-1 binding to the vascular endothelial growth
factor (VEGF) and thereby inhibits angiogenesis [41]. The VEGF
receptor locus is likely to be implicated in both microvascular and
macrovascular diseases although the observed reverse association
with ischemic stroke compared to coronary heart disease in the
diabetics is not immediately explainable. It might be due to
increased VEGF production in diabetic-related haemodynamic
changes [42], larger retinal arteriolar caliber in subjects with
diabetes [9,43,44] and possible selection bias in the diabetic
individuals. More evidence from studies working on diabetics will
be important to elucidate these findings.
Retinal arteriolar caliber is a dynamic anatomic trait that is
affected by many physiologic and behavioral factors such as
hypertension, smoking and changes in response to the cardiac
cycle whereas retinal venular caliber is thought to be, in
comparison, more static. In addition, measurements of the retinal
arteriolar caliber tend to be less precise because there is weaker
colour contrast between the arterioles and the surrounding retina,
whereas venules are more easily demarcated. Hence non-
differential measurement error in the measurement of retinal
arteriolar caliber could be higher than retinal venular caliber
leading to bias findings towards the null and reduced effect
estimates. We might expect some of the genetic determinants of
retinal arteriolar caliber to require larger sample sizes for more
power to detect the genetic effects, if they exist. Some evidence can
be seen from the differences in the intra- and inter-class
correlations of vessel measurements across graders analyzing the
retinal images. Comparatively, the correlations between graders
for arteriolar caliber were lower than those for retinal venular
caliber in each cohort (Text S1). Therefore, it is not surprising that
a larger discovery sample size was required to establish an
association with retinal arteriolar caliber.
We were not able to demonstrate associations between the locus
for retinal arteriolar and any macrovascular disease endpoints,
including coronary artery disease, myocardial infarction, hyper-
tension, and ischemic stroke, despite the reported relationships
between retinal vascular diameters and macrovascular outcomes.
We previously reported one of the variants associated with retinal
venular caliber on chromosome 12q24 near the SH2B3 gene to be
associated with coronary artery disease and hypertension [23].
Reasons for the failure to demonstrate any association between
rs2194025 and common phenotypes of macrovascular disease
Figure 4. Regional association plot at chromosome 5 locus using ARIC data, showing P-values for SNPs for retinal arteriolar caliber
(CRAE), retinal venular caliber (CRVE), retinal arteriolar caliber conditioned on CRAE index SNP rs2194025 and retinal arteriolar
caliber conditioned on CRVE implicated SNP rs17421627.
doi:10.1371/journal.pone.0065804.g004
Genetic Loci for Retinal Arteriolar Caliber
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e65804
endpoints in the current analysis are unclear. One possibility is
that our study was not adequately powered to detect an
association. We estimated the power of our study to detect an
association between rs2194025 and hypertension, given the known
association between retinal arteriolar caliber and hypertension. In
the Blue Mountain Eye Study, the odds ratio of 5-year incident
hypertension was approximately 1.25 per standard deviation
(SD=20 mm) decrease in retinal arteriolar caliber [6,33]. The top
SNP associated with retinal arteriolar caliber (rs2194025) was
associated with a 1.6 mm decrease in retinal arteriolar caliber per
copy of the effective allele. We estimated the odds ratio for the
association between this SNP and hypertension to be 1.02. Given
the allele frequency of this SNP and the sample size for the in-silico
look-up in 9,000 case-control pairs from the Global BPGen
Consortium, our study had less than 10% power to detect an
association with hypertension. Small vessel disease also likely
represents only one of the multiple disease pathways in the
pathogenesis of macrovascular disease outcomes and might have a
more prominent role in the manifestation of disease in its early
stage. Both narrowed retinal arteriolar caliber at baseline and
acquired changes in retinal vessel caliber over time have important
roles in the clinical relevance of macrovascular disease outcomes
[7,12,13]. With just absolute effect sizes estimated from the SNPs
in our cross-sectional study, we are less equipped to finding
relevant associations with clinical outcomes. Heterogeneity in the
clinical phenotypes of the studies of macrovascular disease
outcomes pooled across multiple studies for each genetic
consortium may have also been a factor. Other studies have
observed similar difficulties linking genetic loci associated with a
particular risk marker and subsequently finding relevant associa-
tions with clinical outcomes from clinical epidemiological studies.
For instance, SNPs associated with glycemic traits and high density
lipoproteins are not consistently associated with Type 2 diabetes
[45] and coronary artery disease [46].
Our study consisted of fairly homogenous groups of individuals
of European ancestry and retinal arteriolar caliber was measured
using similar or slightly modified photography techniques,
digitalization methods and computational formulas across the
study cohorts. Further work is needed to fine map existing loci to
localize the causal variants and to investigate the interplay of
genetic and environment modifiers in determining the retinal
vessel calibers. In conclusion, we identified and confirmed a novel
Table 4. Association of the three index SNPs with macrovascular diseases.
SNP (chr: position) Ref/Effective allele (+) Cohort Eff allele freq OR (95% CI) P-value
rs2194025 (5: 87833992) C/G WTCCC (CAD) 2,000 cases/3,000 controls 0.91 1.00 (0.86–1.15) 0.96
HVH (Stroke) 501 cases/1,314 controls 0.91 0.91 (0.69–1.19) 0.50
HVH (MI) 1,172 cases/1,314 controls 0.91 1.01 (0.83–1.24) 0.91
Global BPGen (HTN) ,9,000 case control pairs 0.90 0.95 (0.87–1.03) 0.21
GoDARTS (CAD) 541 cases/2,058 controls` 0.91 1.13 (0.84–1.53) 0.39
GoDARTS (Incident CAD){ 195 cases 0.91 1.00 (0.70–1.42) 0.99
GoDARTS (Incident Ischaemic Stroke) *{ 129 cases 0.91 1.06 (0.69–1.64) 0.79
Cohort Eff allele freq OR (95% CI) P-value
rs3744061 (17: 72244998) A/G WTCCC (CAD) 2,000 cases/3,000 controls 0.45 1.05 (0.97–1.15) 0.21
HVH (Stroke) 501 cases/1,314 controls 0.43 0.96 (0.82–1.13) 0.62
HVH (MI) 1,172 cases/1,314 controls 0.44 1.07 (0.95–1.21) 0.26
Global BPGen (HTN) ,9,000 case control pairs 0.47 1.02 (0.97–1.07) 0.42
GoDARTS (CAD) 541 cases/2,058 controls` 0.41 0.92 (0.78–1.11) 0.39
GoDARTS (Incident CAD){ 195 cases 0.41 0.96 (0.83–1.29) 0.75
GoDARTS (Incident Ischaemic Stroke) *{ 129 cases 0.42 0.93 (0.71–1.23) 0.62
Cohort Eff allele freq Beta (SE) P-value
rs2281827 (13: 27899721) T/C WTCCC (CAD) 2,000 cases/3,000 controls 0.77 1.07 (0.97–1.19) 0.18
HVH (Stroke) 501 cases/1,314 controls 0.75 0.96 (0.78–1.18) 0.70
HVH (MI) 1,172 cases/1,314 controls 0.75 0.99 (0.85–1.15) 0.87
Global BPGen (HTN) ,9,000 case control pairs 0.78 1.01 (0.95–1.07) 0.86
GoDARTS (CAD) 541 cases/2,058 controls` 0.77 1.23 (1.01–1.50) 0.04
GoDARTS (Incident CAD){ 195 cases 0.77 1.22 (0.94–1.59) 0.14
GoDARTS (Incident Ischaemic Stroke) *{ 129 cases 0.77 0.56 (0.42–0.75) 1.1461024
SE: standard error, OR: odds ratio, N: number of incident events, HR: hazards ratio, WTCCC: Wellcome Trust Case Control Consortium, CAD: Coronary Artery Disease, HVH:
Heart and Vascular Health Study, MI: Myocardial infarction, Global BPGen: Global Blood Pressure Genetics Consortium; HTN: hypertension, GoDARTS: Genetics of
Diabetes Audit and Reseach Tayside Scotland.
The allele that decreases retinal arteriolar caliber is presented as the effective allele (refer to Table 2).
*excludes cardioembolic stroke.
`adjusted for age, gender, BMI, history of smoking and hypertension medication.
{adjusted for age, gender, BMI, history of smoking, previous CAD events and previous ischaemic stroke events.
doi:10.1371/journal.pone.0065804.t004
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locus associated with retinal arteriolar caliber. These findings may
shed light on the genetic influence underlying the development of
microvascular disease.
Materials and Methods
Ethics Statement
All cohorts secured approval from their respective institutional
review boards and participants gave written informed consent in
accordance with the Declaration of Helsinki.
Discovery Cohorts
The CHARGE consortium consists of large prospective studies
from the United States and Europe that have genome-wide scans
and well-phenotyped data, measured in a similar way across the
different studies [32]. All participating studies approved guidelines
for collaboration, and working groups arrived at consensus on
phenotype harmonization, covariate selection and analytical plans
for both individual cohort analyses and combined meta-analyses
[32]. Detailed descriptions of each cohort, retinal vessels
measurements and genotyping information are presented in the
Text S1. Briefly, the Age Gene/Environment Susceptibility –
Reykjavik Study (AGES) consists of 5,764 survivors examined
between 2002 to 2006 who were original participants of Iceland’s
Reykjavik Study, a random sample of 30,795 men and women
living in Reykjavik in 1967 and born between 1907 and 1935 [47].
The Atherosclerosis Risk in Communities Study (ARIC) study is a
prospective population-based cohort in the United States,
consisting of 15,792 individuals aged 45 to 64 at baseline (1987–
1989), to study the risk factors of cardiovascular diseases with
yearly follow-up on clinical outcomes [48]. The Cardiovascular
Heart Study (CHS) cohort is a population-based cohort study of
cardiovascular risk factors in 5,201 adults of European descent
recruited in 1989–1990 and 687 African-Americans enrolled in
1992 to 1993 in the United States [49]. The Rotterdam Study (RS)
enrolled 7,983 residents from Rotterdam, The Netherlands who
were aged 55 years and older to study neurogeriatric, cardiovas-
cular, bone, and eye diseases and health in the elderly, with
baseline examination between 1990 and 1993 [50]. The Blue
Mountain Eye Study (BMES) cohort is a population-based cohort
of a predominantly white population aged 49 years or older at
baseline in west Sydney, Australia [24]. From the original cohort,
2,335 participants returned for follow-up examinations during
1997–1999 (BMES IIA) and 1,174 new eligible individuals
participating in an Extension Study of the BMES (BMES IIB)
during 1999 to 2000 formed the population for this study (BMES
cross-sectional II). Only white individuals of European ancestry
from the various cohorts were included in this study.
Replication Cohorts
The Australian Twin Eye Study comprises of 1,769 twins from
the Twins Eye Study in Tasmania (TEST) [26] or the Brisbane
Adolescent Twins Study (BATS) with complete phenotype and
genetic data. The Multi-Ethnic Study of Atherosclerosis (MESA)
was initiated to look into the pathophysiology of subclinical disease
development and progression and its role in clinical cardiovascular
disease in 6,814 individuals aged 45 to 84 years from four ethnic
groups in the United States, including African Americans, Asian,
Hispanic and Whites [25]. Only the non-Hispanic white
participants were included in this study.
Retinal Vascular Caliber Measurements
Retinal vascular caliber was measured using standardized
protocols and software first developed at the University of
Wisconsin. They were first implemented in the ARIC [51] and
CHS [52] studies, and later, with slight modifications, in the RS
[1] and AGES [11]. Participants underwent film or digital retinal
photography and optic disc-centered images (Early Treatment
Diabetic Retinopathy Study ETDRS Field 1) were used to
measure vascular caliber. In addition, pharmacological mydriasis
was used in the AGES and Rotterdam studies. For ARIC, CHS
and RS, the photographs of one eye were digitized using a high-
resolution scanner while for AGES and BMES, digital photo-
graphs of both eyes were captured. All digital retinal images were
analyzed with a semi-automated retinal vessels measurement
system and the calibers of all retinal arterioles and venules were
measured in an area between half and one disc-diameter from the
optic disc margin. The Parr-Hubbard-Knudtson formulas were
used to compute summary measures for retinal arteriolar in the six
largest arterioles and venular calibers in micrometers (mm) [53].
We refer to them as the central retinal arteriolar and venular
equivalents respectively.
Genotyping
The discovery cohorts were genotyped on different genotyping
platforms: Illumina HumanCNV370 for AGES and CHS,
Affymetrix GeneChip SNP Array 6.0for ARIC, Illumina Infinium
II HumanHap 550v3 for RS and Illumina Human670Quadv1
custom chip for BMES. All cohorts were imputed to 2.5 million on
the Hapmap CEU reference panel, after extensive quality control
analyses within each cohort [32].
Statistical Analyses
Each cohort fitted an additive genetic model with one degree of
freedom relating the retinal vessels to genotype dosages (0 to 2
copies) of the effective allele, adjusting for age, sex and study site
whenever necessary. In addition, four multi-dimensional scaling
dimensions were included for the BMES. Linear regression was
used to compute regression coefficients and their standard errors
(SE), using the ProbABEL program (http://mga.bionet.nsc.ru/
y˜urii/ABEL/) [54] in AGES, ARIC, BMES and Rotterdam and
the R software (http://www.r-project.org) in CHS. Genomic
control [55] was applied to each cohort before meta-analysis by
multiplying the square of the genomic control inflation factor lgc
to the SE to account for possible residual population structure or
other confounding factors. The genomic inflation factors for the 5
cohorts ranged from 1.004 to 1.041.
Meta-analysis
We conducted a meta-analysis combining summary results from
linear regression analyses of data from five cohorts of European
descent (AGES, ARIC, CHS, RS and BMES) using an inverse-
variance weighted meta-analysis method with the METAL
software (http://www.sph.umich.edu/csg/abecasis/Metal/index.
html). Strand information was available from all the cohorts, and
all results were synchronized to the forward strand. Overall meta-
analysis inflation factor was 1.03. An a priori genome-wide
significance threshold at P-value ,561028 was used, correspond-
ing to a P-value of 0.05 with Bonferroni correction for one million
independent tests.
Replication-analyses
The two genome-wide significance SNPs from the discovery
stage were further examined in two replication cohorts of
European ancestry, MESA and Australian Twins Study. We also
included one highly suggestive locus for which the P-value was less
than 1026. These index SNPs were examined in-silico in 1,769
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PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e65804
participants from the Australian Twins Study and 2,170 whites
from MESA. Retinal vascular caliber measurements in these
cohorts used the same methodology as in the discovery cohorts
[53,56,57,58,59,60]. Whole-genome genotyping was done using
the Illumina HumanHap610W array for the Australian Twins and
the Affymetrix Genome-Wide Human SNP Array 6.0 for MESA
participants.
Conditional Analyses
Retinal arteriolar and retinal venular vessels are moderately
correlated [33,34]. The primary analyses were subsequently
repeated including retinal venular caliber as a covariate. Condi-
tional analyses were performed at chromosome 5 in two ways on
ARIC data, (i) by including retinal arteriolar caliber index SNP
rs2194025 as a covariate while exploring additional retinal
arteriolar associated SNPs in the region and (ii) by including the
index SNP associated with retinal venular caliber rs17421627 as a
covariate to determine if the SNPs at the same locus remain
associated with arteriolar caliber independent of their associations
with venular caliber.
Analyses with Clinical Endpoints
Finally, we performed in-silico look-ups of the novel and
suggestive variants for several macrovascular outcomes including,
coronary artery disease from the Wellcome Trust Case Control
Consortium (WTCCC) [28], stroke and myocardial infarction
from the Heart and Vascular Health (HVH) Study [29,30],
hypertension from the Global Blood Pressure Genetics (Global
BPgen) Consortium [27] and incident coronary artery disease/
ischemic stroke events from the Genetics of Diabetes Audit and
Research in Tayside Scotland (GoDARTS). To examine the
association of these with macrovascular outcomes, we obtained
summary association statistics for the index SNPs. The WTCCC
coronary artery study consisted of 2,000 coronary artery cases and
3,000 common controls [28]. The HVH study was comprised of
501 stroke cases, 1,172 myocardial infarction and 1,314 controls
[29,30]. In the Global BPGen study, there were approximately
9,000 hypertensive cases and 10,000 controls. The GoDARTS
cohort consisted of 3,328 Type 2 Diabetic individuals with a mean
follow up time of four years. The case-control analysis for coronary
heart disease included 541 cases and 2,038 controls. Survival
analysis to incident macrovascular events included 195 coronary
artery events and 129 ischemic stroke events.
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